

Contents lists available at ScienceDirect

BBA Clinical

journal homepage: www.elsevier.com/locate/bbaclin

Up-regulation of the human-specific *CHRFAM7A* gene in inflammatory bowel disease



Andrew Baird ^{a,*}, Raul Coimbra ^a, Xitong Dang ^{a,b}, Brian P. Eliceiri ^a, Todd W. Costantini ^a

^a Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, USA

^b The Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Sichuan Medical University, Luzhou, China

ARTICLE INFO

Article history:

Received 23 November 2015

Received in revised form 16 December 2015

Accepted 17 December 2015

Available online 8 January 2016

ABSTRACT

Background: The $\alpha 7$ -subunit of the $\alpha 7$ -nicotinic acetylcholine receptor ($\alpha 7$ -nAChR) is an obligatory intermediate for the anti-inflammatory effects of the vagus nerve. But in humans, there exists a second gene called *CHRFAM7A* that encodes a dominant negative $\alpha 7$ -nAChR inhibitor. Here, we investigated whether their expression was altered in inflammatory bowel disease (IBD) and colon cancer.

Methods: Quantitative RT-PCR measured gene expression of human $\alpha 7$ -nAChR gene (*CHRNA7*), *CHRFAM7A*, *TBC3D1*, and actin in biopsies of normal large and small intestine, and compared to their expression in biopsies of ulcerative colitis, Crohn's disease, and colon cancer.

Results: qRT-PCR showed that *CHRFAM7A* and *CHRNA7* gene expression was significantly ($p < .02$) up-regulated in IBD ($N = 64$). Gene expression was unchanged in colon cancer. Further analyses revealed that there were differences in ulcerative colitis and Crohn's Disease. Colon biopsies of ulcerative colitis ($N = 33$) confirmed increased expression of *CHRFAM7A* and decreased in *CHRNA7* expression ($p < 0.001$). Biopsies of Crohn's disease ($N = 31$), however, showed only small changes in *CHRFAM7A* expression ($p < 0.04$) and no change in *CHRNA7*. When segregated by tissue source, both *CHRFAM7A* up-regulation ($p < 0.02$) and *CHRNA7* down-regulation ($p < 0.001$) were measured in colon, but not in small intestine.

Conclusion: The human-specific *CHRFAM7A* gene is up-regulated, and its target, *CHRNA7*, down-regulated, in IBD. Differences between ulcerative colitis and Crohn's disease tie to location of disease.

Significance: The appearance of IBD in modern humans may be consequent to the emergence of *CHRFAM7A*, a human-specific $\alpha 7$ -nAChR antagonist. *CHRFAM7A* could present a new, unrecognized target for development of IBD therapeutics.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The emergence of human-specific genes (HSG) in the course of human evolution are presumed to have enabled the adaptation of humans to new environments and new behaviors [1–9] but their specific physiological functions are often unknown. The human-specific *CHRFAM7A* gene is a case in point. First, it encodes a uniquely human and independently regulated subunit of the $\alpha 7$ -nicotinic acetylcholine receptor ($\alpha 7$ -nAChR) that regulates neurotransmitter function. Therefore, it is presumed to affect CNS function. When co-expressed with $\alpha 7$ -nAChR, however, *CHRFAM7A* is a dominant negative regulator of neurotransmitter binding to, and activation of, the $\alpha 7$ -nAChR, thereby potentially altering the central nervous system functions of $\alpha 7$ -nAChR

in its regulation of processes like cognition, memory, and mental health [10–19].

But *CHRFAM7A* is also widely expressed in leukocytes and epithelial cells [11,19–21], where it is presumed to regulate the powerful anti-inflammatory effects of $\alpha 7$ -nAChR activation [22–24]. Because the activation of $\alpha 7$ -nAChR is an obligatory intermediate for vagus nerve control of inflammation [25], *CHRFAM7A* in humans must therefore regulate the anti-inflammatory vagus nerve. If so, it raises the possibility that *CHRFAM7A* expression in peripheral tissues [20,21] could be associated with human inflammatory disease like, for example, inflammatory bowel disease (IBDs).

IBDs have complex molecular etiologies of genetic, epigenetic, microbial, and environmental origin that present as highly heterogeneous episodes of gut inflammation [26,27], making animal modeling difficult [28]. Accordingly, the response of IBDs to behavioral, dietary, and therapeutic interventions is often enigmatic, as exemplified by both protective and deleterious effects of nicotine and nicotine withdrawal on its remission, recurrence, and treatment [26,27]. Here, we explored the

* Corresponding author at: Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA 98896, USA.

E-mail address: anbaird@ucsd.edu (A. Baird).

possibility that a concomitant, but differentially regulated [20,21] expression of the human-specific and pro-inflammatory *CHRFAM7A* gene and its anti-inflammatory $\alpha 7$ -nAChR target [11,19,24,25] (*CHRNA7*), could be implicated in IBD.

2. Materials and methods

2.1. Biopsies of inflammatory bowel disease and colon cancer

cDNAs in OriGene TissueScan Arrays from characterized biopsies of ulcerative colitis (CCRT101 and CCRT 102), Crohn's disease (CCRT101 and CCRT 102), or colon cancer (HCRT104) were used to assess gene expression in disease (N = 109) and control (N = 19) tissue biopsies. All characteristics of these specimens are available online with detailed clinical information, histology slides of each biopsy, and the quality control data for RNA isolation and cDNA preparations at California <http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx>. The original de-identified tissues were collected from accredited medical institutions in the United States using IRB-approved protocols, selected by board-certified pathologists and then deposited into the OriGene tissue biorepository along with all of the available clinical data supporting the pathology diagnoses. The specific array plates used contained cDNA synthesized prepared from RNA extracted from these pathologist-verified tissues. The


quantity of cDNA was normalized, first validated with β -actin at OriGene and the findings replicated in the course of the gene expression studies described here. The Ct value of actin gene expression in each well was determined in our laboratories was highly consistent (average 20.89 cycles \pm 0.1 (SEM, N = 135)) and the individual values from each well used to calculate relative gene expression in each biopsy using the actin primers, as specifically noted by the array manufacturer.

2.2. PCR, primers, and the conditions for *CHRFAM7A*, *CHRNA7*, and *TBC1D3* analyses

The PCR reaction was performed in 50 μ l containing 45 μ l PCR blue mix (Invitrogen), 1 μ l of each primer (10 μ M), 300 ng cDNA, and 2 μ l water. The cycling conditions were 94 $^{\circ}$ C for 4 min followed by 35 cycles of 94 $^{\circ}$ C for 30 s, 60 $^{\circ}$ C for 30 s, and 72 $^{\circ}$ C for 60 s, and a final extension at 72 $^{\circ}$ C for 5 min. Ten microliters of each PCR product was resolved on a 2% agarose gel and images were acquired using Alpha Innotech imaging system. Real-time qPCR was performed in a 25 μ l reaction containing 12.5 μ l 2 \times CYBR Green PCR Master Mix (BioRad), 0.5 μ l of each primer (10 μ M), 1 μ l cDNA, and 10.5 μ l water. PCR cycling conditions were 95 $^{\circ}$ C for 10 min followed by 45 cycles of 94 $^{\circ}$ C for 25 s, 60 $^{\circ}$ C for 25 s, and 72 $^{\circ}$ C for 40 s. Primer efficiency for *CHRFAM7A* and *CHRNA7* were 100% and 94%, respectively.

Table 1
Tissue biopsies.

	Ulcerative colitis	Crohn's disease	Colon cancer			
<i>Array ID</i>	CCRT101/102	CCRT101/102	HCRT104			
<i>Biopsies studied</i>	44	42	48			
Normal		11	8			
Disease	33	31	40			
<i>Control biopsies</i>						
<i>Location of lesion</i>		Colon 8 Small Intestine 3	Colon 8			
<i>Gender</i>						
Male		7	2			
Female		4	6			
<i>Age (years)</i>		54 (26–89)	78 (60–89)			
Male		56 (26–89)	82 (81–82)			
Female		50 (29–70)	77 (60–89)			
<i>% Mucosa</i>		48% (10–90)	N/A			
Male		50% (20–85)	N/A			
Female		44% (10–90)	N/A			
<i>Disease biopsies</i>			<i>Tissue</i>	<i>Stage</i>	<i>N</i>	
<i>Location of lesion</i>	Colon 33 Small Intestine 0	Colon 13 Small Intestine 18	Colon Colon Colon Colon	I II III IV	5 9 16 10	
<i>Gender</i>						
Male	21	14			16	
Female	12	17			24	
<i>Age (years)</i>	39 (22–76)	38 (19–65)			68 (21–89)	
Male	38 (22–72)	40 (20–64)			65 (21–82)	
Female	45 (26–76)	36 (19–65)			70 (45–89)	
<i>% Mucosa/differentiation*</i>	43% (10–100)	38 (0–00)	Well Moderate Poor Un-diff.			
Male	43% (10–100)	41 (0–80)	10 7 3	19 11 8	6 4 2	5 2 3
Female	43% (10–95)	35 (10–90)				
<i>Pathology</i>						
<i>Lesion/tumor (%)</i>		100			71% (25–95%)	
Male		100			69.9 (25–95)	
Female		100			73.7 (40–90)	
<i>Hypercellular stroma (%)</i>		N/A			16% (0–55%)	
Male		N/A			17.3 (0–55%)	
Female		N/A			14.4 (0–35%)	
<i>Hypocellular Stroma (%)</i>		N/A			1.95% (0–28%)	
Male		N/A			2.7 (0–28%)	
Female		N/A			0.9 (0–10%)	
<i>Necrosis (%)</i>		0			4.9% (0–40%)	
Male		0			3.6% (0–40%)	
Female		0			6.6 (0–20%)	



Expression of CHRNA7 and CHR FAM7A was normalized to that of β -actin using $\Delta\Delta$ Ct method and primers provided by the manufacturer of tissue arrays. Primers for CHR FAM7A were designed to hybridize with the variant 1 transcript by selecting oligonucleotide sequences bridging shared CHR FAM7A and CHRNA7 sequences and therefore unique to CHR FAM7A and not available in CHR FAM7A or CHRNA7A alone.

Sense:	5'-ATAGCTGCAAAC TCGGATA-3'
Anti-sense:	5'-CAGCGTACATCGATGTAGCAG-3'

Primers for CHRNA7 were designed to hybridize with both variant 1 and 2 transcripts of human CHRNA7 by selecting oligonucleotide sequences that are present in both variants of human CHRNA7 but absent from CHR FAM7A.

Sense:	5'-ACATGCGCTGCTCGCGGA-3'
Anti-sense:	5'-GATTGTAGTCTTGACCAGCT-3'

Primers for TBC1D3 were selected based on previously published findings [29]:

Sense:	5'-GCATCGACCGGGACGTAAG-3'
Anti-sense:	5'-CCTCCGGGTGTACTCTCAT-3'

2.3. Analyses of gene expression

CHR FAM7A, CHRNA7, TBC1D3, and actin gene expression were measured as described above and normalized to that of β -actin or as indicated, to CHRNA7 expression, in each sample. The fold change in gene expression was calculated by $\Delta\Delta$ Ct method and analyzed using the relative expression software tool (REST) for group-wise comparisons of relative expression [30]. The GraphPad program PRISM6 was used for preparation of figures.

3. Results and discussion

The characteristics of the commercially available gene expression arrays of human IBD and colon cancer used in these studies are publicly available <http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx> and include information regarding gender, age, tissue of origin, case diagnosis from donor institutions, histological sections, and pathology verification reports. The latter also includes the percentage of mucosa/differentiation, lesion, and inflammation and are summarized in Table 1.

3.1. CHR FAM7A and the gene encoding human α 7-nAChR (CHRNA7) are differentially expressed in IBD

Initially, quantitative RT-PCR of biopsies (N = 64) from patients with IBD suggested that there was only a small, albeit significant ($p < 0.05$) increase in CHR FAM7A gene expression (Fig. 1A) compared to biopsies from control tissue. In cDNA prepared from these same biopsies, there was no significant difference in CHRNA7 gene expression (Fig. 1B) although the ratio of CHR FAM7A/CHRNA7 gene expression (Fig. 1C) was different in IBD ($p < 0.02$) compared with controls.

In contrast, when we compared CHR FAM7A and CHRNA7 gene expression in the two distinct forms of disease represented in IBD (ulcerative colitis and Crohn's disease), a significant pattern emerged. First, colon biopsies from patients with ulcerative colitis (N = 33) confirmed the global increase in expression of CHR FAM7A (Fig. 1D), but now the analyses revealed that there was a concomitant and significant ($p < 0.001$) decrease in CHRNA7 expression in ulcerative colitis (Fig. 1E).

These changes in ulcerative colitis were also highly significant ($p < 0.001$) when comparing CHRNA7 expression to that of CHR FAM7A (Fig. 1F). In Crohn's disease (N = 31), there was a small but significant ($p < 0.04$) increase in CHR FAM7A gene expression (Fig. 1G) but no significant change in CHRNA7 expression (Fig. 1H). As earlier, normalization of CHR FAM7A with CHRNA7 expression increased the significance of the difference ($p < 0.02$, Fig. 1I).

Ulcerative colitis affects colon and not small intestine but Crohn's disease can affect any portion of the gastrointestinal tract [26,27]. In analyzing the source of biopsy (Fig. 1J, K, and L), we observed a significant ($p < 0.02$) up-regulation in CHR FAM7A gene expression in colon from patients with Crohn's disease (Fig. 1J), but there was also a concomitant and significant ($p < 0.001$) down-regulation in CHRNA7 (Fig. 1K) underscored by the significant change of CHR FAM7A when normalized with CHRNA7 (Fig. 1K). In small intestine biopsies of Crohn's disease, the change in CHR FAM7A (Fig. 1M), CHRNA7 (Fig. 1N) or in the ratio of CHR FAM7A to CHRNA7 (Fig. 1O) was not significant.

3.2. The changes in CHR FAM7A and CHRNA7 are specific

We used two approaches to establish specificity of differential expression in diseased colon. First, we evaluated the expression of CHR FAM7A (Fig. 2A and D), CHRNA7 (Fig. 2B and E), and CHR FAM7A-to-CHRNA7 ratio (Fig. 2C and F) in colon cancer biopsies. No differences were detected when all colon cancer biopsies were evaluated together (Fig. 1A, B, C) or when analyzed according to the stage of disease (Fig. 1D, E, F). Second, we evaluated the expression of a second human-specific gene called TBC1D3, that is associated with macro-pinocytosis and epidermal growth factor signaling [29]. There were no differences in IBD, no differences in either ulcerative colitis or Crohn's disease when examined separately. There were also no differences in gene expression of TBC1D3 in biopsies from colon cancer (Fig. 2G, H, I). This concordance of CHR FAM7A and CHRNA7 expression in colon cancer is also evident in curated public databases like the Cancer Genome Atlas (www.cbioportal.org), which enables mining gene expression patterns in different epithelial cancers. Correlations between CHR FAM7A and CHRNA7 in these databases are >0.87 (Pearson) and >0.77 (Spearman) in uterine, stomach, and colorectal cancers). Unfortunately, no analogous public databases with RNAseq data exist for inflammatory bowel disease, Crohn's disease, or ulcerative colitis, although several studies have evaluated whole genome gene expression [31–33] and found changes in, and effects of, traditional inflammatory products like TNF and HMBG1 [34,35].

In 2011, Cooper and Kehrer-Sawatzki [8] reported that new human genes [2,3,5,7–9] are over-represented among genes tied to complex human disease and more recently [36] described how newly evolved human genes can drive gene interaction networks associated with critical phenotypes. It is in this vein that the results presented here suggest that the up-regulation of pro-inflammatory CHR FAM7A in humans could exacerbate the down-regulation of anti-inflammatory α 7-nAChR in IBD. If so, it is interesting to speculate that this pro-inflammatory effect of CHR FAM7A expression is an "off-target" contributor to human IBD that arose as a function of adaptation (Fig. 2J, K). In this paradigm, a human-specific gene like CHR FAM7A could have originally arisen as an evolutionary pro-inflammatory and adaptive response to newly emerging human behaviors like bipedal walking (trauma) or the harnessing of fire (burn injury) but retained for CNS activities regulating neurotransmitter activity. Interestingly, human-specific responses in gene expression after trauma, burn, and infection have been previously described [37], although they remain controversial largely because of

Fig. 1. CHR FAM7A and CHRNA7 gene expression in inflammatory bowel disease (IBD). Quantitative RT-PCR was used to measure CHR FAM7A and CHRNA7 gene expression in intestinal biopsies from patients with IBD (panels A–C), ulcerative colitis (panels D–F), and Crohn's disease (panels G–J). Gene expression in each sample was normalized to that of actin or, as indicated, between each other to determine the CHR FAM7A/CHRNA7 ratio. Relative gene expression was compared to that in control biopsies using the $\Delta\Delta$ Ct method. Differences in gene expression between the control and disease biopsies were measured by REST [30] for group-wise comparisons and evaluated as either individual plates and after combination (shown).




Fig. 2. Changes in CHRFAM7A and CHRNA7 gene expression are specific for IBD. Quantitative RT-PCR was used to measure CHRFAM7A and CHRNA7 gene expression in biopsies of colon cancer (panels A–F) as all biopsies (panels A–C) or by colon cancer stage (panels D–F). Gene expression in each sample was normalized to that of actin or, as indicated, between CHRFAM7A and CHRNA7 using the ΔC_t method. Relative gene expression was then compared to that in control biopsies using the $\Delta\Delta C_t$ method. Differences in gene expression between the control and disease biopsies were measured by REST [30] for group-wise comparisons and no differences were found to be significant at $p < 0.05$. Expression of the human-specific gene TBCD1 from all IBD samples (panel G), in Crohn's and ulcerative colitis (panel H) or in colon cancer (panel I) were also unchanged. As illustrated in panel J, new genes emerge in new environments to adapt to new behaviors like bipedal behavior (trauma) and the harnessing of fire (burn/sepsis) and alter responsiveness. Off-target effects (panel K) for example regulating $\alpha 7nAChR$ activity in neurons might prove even more important than the original pro-inflammatory selection but the sequelae for human disease tied to original (inflammation) and unanticipated (mental health) effects of gene expression.

their implications to animal modeling of human injury [38,39]. Ironically, the putative adaptive pro-inflammatory origin of a hominid gene like CHRFAM7A may ultimately be ancillary to its physiological significance to human speciation because CHRFAM7A in the brain is tied to regulating $\alpha 7nAChR$, a ligand-gated neurotransmitter channel that itself regulates human cognition, attention, memory, and mental health. In this model, the up-regulation of CHRFAM7A in peripheral tissues of modern humans could reflect vestigial pro-inflammatory activity. Such a possible paradigm underscores the importance of understanding the role of human evolution in the etiology of human disease, the role of HSGs, and ultimately, their function when modeling human disease.

On a final note, the differential expression of the CHRFAM7A human-specific gene in a prototypic human disease like IBD underscores the importance of better understanding the contribution of this class of genes to the onset, development, and progression human disease when diseases are modeled in experimental animals. With newly emerged human-specific genes like ARHGAP11B promoting neocortex expansion *in vivo* [40], c20orf203 eliciting differential gene function [41], human-specific defensins conferring differential resistance to infection [42], and CD33 providing cognitive protection [43], it is critical to understand the possible contributions of newly evolved gene interaction networks to human disease when they differ in humans from all other species and create unique phenotypes [36].

Author contributions

Conceived of experiments and wrote first drafts of manuscript (AB), designed PCR and validated qPCR (XD), assisted in interpretation of data and assisted in preparation of brief report (RC, BE, and TC).

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Acknowledgments

The authors would like to thank Ms. Emelie Amburn for expert technical assistance and support by the American College of Surgeons C. James Carrico Faculty Research Fellowship (to T.W. Costantini), NIH Grant R01CA170140 (to B.P. Eliceiri), and the Reinvestment Fund of the UC San Diego Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery.

References

- [1] X. Wang, N. Mitra, I. Secundino, K. Banda, P. Cruz, V. Padler-Karavani, A. Verhagen, C. Reid, M. Lari, E. Rizzi, et al., Specific inactivation of two immunomodulatory SIGLEC genes during human evolution, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 9935–9940.
- [2] S. Chen, B.H. Krinsky, M. Long, New genes as drivers of phenotypic evolution, *Nat. Rev. Genet.* 14 (2013) 645–660.
- [3] M. Long, N.W. VanKuren, S. Chen, M.D. Vbranovski, New gene evolution: little did we know, *Annu. Rev. Genet.* 47 (2013) 307–333.
- [4] N.G. Smith, A. Eyre-Walker, Human disease genes: patterns and predictions, *Gene* 318 (2003) 169–175.
- [5] D. Tautz, T. Domazet-Loso, The evolutionary origin of orphan genes, *Nat. Rev. Genet.* 12 (2011) 692–702.
- [6] A. Varki, T.K. Altheide, Comparing the human and chimpanzee genomes: searching for needles in a haystack, *Genome Res.* 15 (2005) 1746–1758.
- [7] Y.E. Zhang, P. Landback, M. Vbranovski, M. Long, New genes expressed in human brains: implications for annotating evolving genomes, *BioEssays: news and reviews in molecular, cellular and developmental biology*, 34 2012, pp. 982–991.
- [8] D.N. Cooper, H. Kehrler-Sawatzki, Exploring the potential relevance of human-specific genes to complex disease, *Hum. Genet.* 5 (2011) 99–107.
- [9] H. Huang, E.E. Winter, H. Wang, K.G. Weinstock, H. Xing, L. Goodstadt, P.D. Stenson, D.N. Cooper, D. Smith, M.M. Alba, et al., Evolutionary conservation and selection of human disease gene orthologs in the rat and mouse genomes, *Genome Biol.* 5 (2004) R47.
- [10] E. Bacchelli, A. Battaglia, C. Cameli, S. Lomartire, R. Tancredi, S. Thomson, J.S. Sutcliffe, E. Maestrini, Analysis of CHRNA7 rare variants in autism spectrum disorder susceptibility, *Am. J. Med. Genet. A* (2015).
- [11] T.W. Costantini, X. Dang, R. Coimbra, B.P. Eliceiri, A. Baird, CHRFAM7A, a human-specific and partially duplicated alpha7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury, *J. Leukoc. Biol.* 97 (2015) 247–257.

- [12] V. De Luca, O. Likhodi, H.H. Van Tol, J.L. Kennedy, A.H. Wong, Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia, *Acta Psychiatr. Scand.* 114 (2006) 211–215.
- [13] E.L. Dempster, T. Touloupoulou, C. McDonald, E. Bramon, M. Walshe, H. Wickham, P.C. Sham, R.M. Murray, D.A. Collier, Episodic memory performance predicted by the 2 bp deletion in exon 6 of the “alpha 7-like” nicotinic receptor subunit gene, *Am. J. Psychiatry* 163 (2006) 1832–1834.
- [14] R.H. Flomen, D.A. Collier, S. Osborne, J. Munro, G. Breen, D. St Clair, A.J. Makoff, Association study of *CHRFAM7A* copy number and 2 bp deletion polymorphisms with schizophrenia and bipolar affective disorder, *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 141B (2006) 571–575.
- [15] J. Gault, J. Hopkins, R. Berger, C. Drebing, J. Logel, C. Walton, M. Short, R. Vianzon, A. Olincy, R.G. Ross, et al., Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects, *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 123B (2003) 39–49.
- [16] C.J. Hong, I.C. Lai, L.L. Liou, S.J. Tsai, Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder, *Neurosci. Lett.* 355 (2004) 69–72.
- [17] M. Neri, S. Bonassi, P. Russo, Genetic variations in *CHRNA7* or *CHRFAM7* and susceptibility to dementia, *Curr. Drug Targets* 13 (2012) 636–643.
- [18] N. Petrovsky, A. Schmechtig, R.H. Flomen, V. Kumari, D. Collier, A. Makoff, M. Wagner, U. Ettinger, *CHRFAM7A* copy number and 2-bp deletion polymorphisms and antisaccade performance, *Int. J. Neuropsychopharmacol.* 12 (2009) 267–273.
- [19] M.L. Sinkus, S. Graw, R. Freedman, R.G. Ross, H.A. Lester, S. Leonard, The human *CHRNA7* and *CHRFAM7A* genes: a review of the genetics, regulation, and function, *Neuropharmacology* (2015).
- [20] T.W. Costantini, X. Dang, M.V. Yurchyshyna, R. Coimbra, B.P. Eliceiri, A. Baird, A human-specific alpha7-nicotinic acetylcholine receptor gene in human leukocytes: identification, regulation and the consequences of *CHRFAM7A* expression, *Mol. Med.* (2015) <http://dx.doi.org/10.2119/molmed.2015.00018>.
- [21] X. Dang, B.P. Eliceiri, A. Baird, T.W. Costantini, *CHRFAM7A*: a human-specific alpha7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS, *FASEB J.* (2015) <http://dx.doi.org/10.1096/fj.14-268037>.
- [22] T. Araud, S. Graw, R. Berger, M. Lee, E. Neveu, D. Bertrand, S. Leonard, The chimeric gene *CHRFAM7A*, a partial duplication of the *CHRNA7* gene, is a dominant negative regulator of alpha7nAChR function, *Biochem. Pharmacol.* 82 (2011) 904–914.
- [23] A.M. de Lucas-Cerrillo, M.C. Maldifassi, F. Amalich, J. Renart, G. Atienza, R. Serantes, J. Cruces, A. Sanchez-Pacheco, E. Andres-Mateos, C. Montiel, Function of partially duplicated human alpha77 nicotinic receptor subunit *CHRFAM7A* gene: potential implications for the cholinergic anti-inflammatory response, *J. Biol. Chem.* 286 (2011) 594–606.
- [24] Y. Wang, C. Xiao, T. Indersmitten, R. Freedman, S. Leonard, H.A. Lester, The duplicated alpha7 subunits assemble and form functional nicotinic receptors with the full-length alpha7, *J. Biol. Chem.* (2014).
- [25] H. Wang, M. Yu, M. Ochani, C.A. Amella, M. Tanovic, S. Susarla, J.H. Li, H. Wang, H. Yang, L. Ulloa, et al., Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation, *Nature* 421 (2003) 384–388.
- [26] J.K. Ko, K.K. Auyeung, Inflammatory bowel disease: etiology, pathogenesis and current therapy, *Curr. Pharm. Des.* 20 (2014) 1082–1096.
- [27] N.A. Molodecky, I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, G. Chernoff, E.I. Benchimol, R. Panaccione, S. Ghosh, H.W. Barkema, et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, *Gastroenterology* 142 (46–54) (2012) e42 (quiz e30).
- [28] D. Low, D.D. Nguyen, E. Mizoguchi, Animal models of ulcerative colitis and their application in drug research, *Drug Des. Devel. Ther.* 7 (2013) 1341–1357.
- [29] M.J. Wainszelbaum, J. Liu, C. Kong, P. Srikanth, D. Samovski, X. Su, P.D. Stahl, *TBC1D3*, a hominoid-specific gene, delays IRS-1 degradation and promotes insulin signaling by modulating p70 S6 kinase activity, *PLoS One* 7 (2012), e31225.
- [30] M.W. Pfaffl, G.W. Horgan, L. Dempfle, Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR, *Nucleic Acids Res.* 30 (2002), e36.
- [31] A.H. Mirza, C.H. Berthelsen, S.E. Seemann, X. Pan, K.S. Frederiksen, M. Vilien, J. Gorodkin, F. Pociot, Transcriptomic landscape of lncRNAs in inflammatory bowel disease, *Genome Med.* 7 (2015) 39.
- [32] A. Granlund, A. Flatberg, A.E. Ostvik, I. Drozdov, B.I. Gustafsson, M. Kidd, V. Beisvag, S.H. Torp, H.L. Waldum, T.C. Martinsen, et al., Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis, *PLoS One* 8 (2013), e56818.
- [33] Y. Iboshi, K. Nakamura, E. Ihara, T. Iwasa, H. Akiho, N. Harada, M. Nakamura, R. Takayanagi, Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn's disease, *Inflamm. Bowel Dis.* 20 (2014) 967–977.
- [34] D.A. van Heel, I.A. Udalova, A.P. De Silva, D.P. McGovern, Y. Kinouchi, J. Hull, N.J. Lench, L.R. Cardon, A.H. Carey, D.P. Jewell, et al., Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(–kappa)B transcription factors, *Hum. Mol. Genet.* 11 (2002) 1281–1289.
- [35] R. Vitali, L. Stronati, A. Negroni, G. Di Nardo, M. Pierdomenico, E. del Giudice, P. Rossi, S. Cucchiara, Fecal HMGBl is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease, *Am. J. Gastroenterol.* 106 (2011) 2029–2040.
- [36] W. Zhang, P. Landback, A.R. Gschwend, B. Shen, M. Long, New genes drive the evolution of gene interaction networks in the human and mouse genomes, *Genome Biol.* 16 (2015) 202.
- [37] J. Seok, H.S. Warren, A.G. Cuenca, M.N. Mindrinos, H.V. Baker, W. Xu, D.R. Richards, G.P. McDonald-Smith, H. Gao, L. Hennessy, et al., Genomic responses in mouse models poorly mimic human inflammatory diseases, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 3507–3512.
- [38] K. Takao, T. Miyakawa, Genomic responses in mouse models greatly mimic human inflammatory diseases, *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) 1167–1172.
- [39] M.F. Osuchowski, D.G. Remick, J.A. Lederer, C.H. Lang, A.O. Aasen, M. Aibiki, L.C. Azevedo, S. Bahrami, M. Boros, R. Cooney, et al., Abandon the mouse research ship? Not just yet! *Shock* 41 (2014) 463–475.
- [40] M. Florio, M. Albert, E. Taverna, T. Namba, H. Brandl, E. Lewitus, C. Haffner, A. Sykes, F.K. Wong, J. Peters, et al., Human-specific gene *ARHGAP11B* promotes basal progenitor amplification and neocortex expansion, *Science* 347 (2015) 1465–1470.
- [41] C.Y. Li, Y. Zhang, Z. Wang, Y. Zhang, C. Cao, P.W. Zhang, S.J. Lu, X.M. Li, Q. Yu, X. Zheng, et al., A human-specific de novo protein-coding gene associated with human brain functions, *PLoS Comput. Biol.* 6 (2010), e1000734.
- [42] D.Q. Cheng, Y. Li, J.F. Huang, Molecular evolution of the primate alpha –/theta-defensin multigene family, *PLoS One* 9 (2014), e97425.
- [43] F. Schwarz, S.A. Springer, T.K. Altheide, N.M. Varki, P. Gagneux, A. Varki, Human-specific derived alleles of *CD33* and other genes protect against postreproductive cognitive decline, *Proc. Natl. Acad. Sci. U. S. A.* (2015).